Evidence map›Paper›PMID 25050113›Full record

ArticleJournal of biomedical research2014

Luteolin prevents uric acid-induced pancreatic β-cell dysfunction.

Ying Ding, Xuhui Shi, Xuanyu Shuai, Yuemei Xu, Yun Liu, Xiubin Liang, Dong Wei, Dongming Su

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ying DingCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Xuhui ShiCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Xuanyu ShuaiCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Yuemei XuCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Yun LiuCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Xiubin LiangCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Dong WeiDepartment of Endocrinology, the Second People's Hospital of Chengdu, Sichuan 610017, China.
Dongming SuCenter of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China. ; Center of Cellular Therapy, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Nanjing Medical University · CNChengdu Second People's Hospital · CNSecond Affiliated Hospital of Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated uric acid causes direct injury to pancreatic β-cells. In this study, we examined the effects of luteolin, an important antioxidant, on uric acid-induced β-cell dysfunction. We first evaluated the effect of luteolin on nitric oxide (NO) formation in uric acid-stimulated Min6 cells using the Griess method. Next, we performed transient transfection and reporter assays to measure transcriptional activity of nuclear factor (NF)-κB. Western blotting assays were also performed to assess the effect of luteolin on the expression of MafA and inducible NO synthase (iNOS) in uric acid-treated cells. Finally, we evaluated the effect of luteolin on uric acid-induced inhibition of glucose-stimulated insulin secretion (GSIS) in Min6 cells and freshly isolated mouse pancreatic islets. We found that luteolin significantly inhibited uric acid-induced NO production, which was well correlated with reduced expression of iNOS mRNA and protein. Furthermore, decreased activity of NF-κB was implicated in inhibition by luteolin of increased iNOS expression induced by uric acid. Besides, luteolin significantly increased MafA expression in Min6 cells exposed to uric acid, which was reversed by overexpression of iNOS. Moreover, luteolin prevented uric acid-induced inhibition of GSIS in both Min6 cells and mouse islets. In conclusion, luteolin protects pancreatic β-cells from uric acid-induced dysfunction and may confer benefit on the protection of pancreatic β-cells in hyperuricemia-associated diabetes.

Indexed as

luteolinMafAnitric oxidenuclear factor (NF)-κBuric acid

Identifiers

PMID25050113
PMCPMC4102843
OpenAlexW2145688661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.